What is VisionGate?
VisionGate operates within the biotechnology sector, specializing in the early detection of lung cancer through innovative, non-intrusive testing methods. Leveraging 3D cellular imaging and AI-powered technology for sputum sample analysis, the company aims to improve diagnostic precision and patient outcomes. With a robust portfolio of 35 patents, VisionGate is positioned to make a substantial impact on cancer screening protocols, particularly for individuals at higher risk. The company's commitment extends to raising public awareness and providing resources for both medical professionals and patients.
How much funding has VisionGate raised?
VisionGate has raised a total of $57.7M across 6 funding rounds:
Private Equity
$1.8M
Private Equity
$4.4M
Debt
$5.3M
Private Equity
$20M
Private Equity
$26.1M
Debt
$150K
Private Equity (2008): $1.8M, investors not publicly disclosed
Private Equity (2010): $4.4M, investors not publicly disclosed
Debt (2014): $5.3M, investors not publicly disclosed
Private Equity (2017): $20M featuring Trinnovate Ventures
Private Equity (2017): $26.1M backed by Undisclosed
Debt (2020): $150K with participation from PPP
Key Investors in VisionGate
Trinnovate Ventures
Trinnovate Ventures is an investment firm focused on healthcare innovations that enhance efficiency and quality within the healthcare experience. They invest in and develop strategic healthcare-related partnerships.
What's next for VisionGate?
The recent major strategic investment signals a pivotal growth phase for VisionGate. This capital infusion is anticipated to fuel further research and development, potentially expanding the company's technological capabilities and patent portfolio. Strategic partnerships and market penetration efforts are likely to be prioritized, aiming to integrate VisionGate's advanced detection methods into mainstream healthcare practices. The company's focus on improving lung cancer detection accuracy suggests a trajectory towards becoming a leader in oncological diagnostics, with future funding rounds likely aimed at scaling operations and commercializing its patented technologies.
See full VisionGate company page
